Lykov A.P.,FSBI ICEL SB RAMS |
Poveschenko O.V.,FSBI ICEL SB RAMS |
Kim I.I.,FSBI ICEL SB RAMS |
Bondarenko N.A.,FSBI ICEL SB RAMS |
And 4 more authors.
Russian Journal of Biopharmaceuticals | Year: 2014
Therapeutic efficacy of autologous lymphocytes, activated by ronkoleukin in patients with lymphedema complicated with recurrent erysipelatous were studied. It was shown that adminis- tration of recombinant interleukin 2 (ronkoleukin) activated autologous lymphocytes in patients with erysipelas leads to the rehabilitation of lymphocyte population contents and to clinical efficacy (reduction of expressiveness of hypostasis of soft fabrics and recurrence of an erysipelatous inflammation).